Michael A. Metzger - 06 Feb 2023 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Chief Executive Officer, Director
Signature
/s/ Michael A. Metzger
Issuer symbol
SNDX
Transactions as of
06 Feb 2023
Net transactions value
-$291,376
Form type
4
Filing time
08 Feb 2023, 15:49:37 UTC
Previous filing
03 Feb 2023
Next filing
07 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $38,018 +5,959 +34% $6.38 23,618 06 Feb 2023 Direct
transaction SNDX Common Stock Sale $164,697 -5,959 -25% $27.64 17,659 06 Feb 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $164,697 -5,959 -100% $27.64 0 06 Feb 2023 Common Stock 5,959 $6.38 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 735,987 options to purchase shares of common stock that are vested and immediately exercisable and a total of 809,583 options to purchase shares of common stock that have not yet vested.
F2 The sale prices ranged from $27.50 to $27.84.
F3 This option is fully vested.